Trending Topics in ND Webinar Series
22 SEPTEMBER // 1:00 PM ET
A Biological Definition and Integrated Staging System for Parkinson’s Disease
With guest speaker, Luis Miguel Oliveira, PhD
Senior Associate Director, Research Programs The Michael J. Fox Foundation for Parkinson’s Research
ABOUT LUIS OLIVEIRA
Luis Miguel Oliveira is an expert in the field of Parkinson’s disease research and investment with more than 15 years of experience in the neurologic diseases space. Currently, he holds the position of Senior Associate Director of Research Programs at The Michael J. Fox Foundation, where he leads various efforts for therapeutic and biomarker development in priority genetic targets for Parkinson’s disease accounting for over $30 million in executed projects. Additionally, Luis Miguel Oliveira is a founder of v-ATPase Alliance, an organization aimed at connecting families affected by rare diseases related to v-ATPase with the research and medical communities for further advancing therapeutic development. With a strong commitment to advance novel treatments from the bench to bedside, Luis Miguel Oliveira serves as a Review Editor for Frontiers in Neurology, Neuroscience and Psychiatry, and as an Investment Advisor for Portugal Ventures, where he leverages his expertise to guide investment decisions in promising ventures. Recently, Luis Miguel Oliveira had an integral contribution to a landmark study that validated the first biomarker for Parkinson’s disease diagnosis. This significant achievement was reported in Lancet Neurology with broader international media coverage and is changing the Parkinson’s research and drug development fields by enabling an objective characterization of the disease based on its biological features. Luis Miguel Oliveira’s educational background includes a degree in Biochemistry from the Faculty of Sciences of Lisbon University in Portugal. He further pursued his academic journey with a PhD in Molecular Biophysics from the same institution. During his postdoctoral research experience, he conducted his studies at renowned institutions such as the Max Planck Institute for Biophysical Chemistry in Germany and Columbia University in New York.
